google-site-verification: googlec7193c3de77668c9.html

Low-cost treatment for multiple sclerosis shown to be as effective as standard therapy

[
A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS). The study, known as OVERLORD-MS, is the first randomized, double-blind, head-to-head trial comparing the two therapies in early MS. Patients from across Norway and Sweden were followed for 30 months with MRI and clinical assessments.


Source link

Advertisements
Views: 1

See also  MadeGood granola bars recalled because they could contain pieces of metal

Check Also

CDC urges people to prevent mosquito bites as West Nile virus season hits a strong, early start

[ A municipal biologist examines a mosquito in Salt Lake City, Aug. 26, 2019. Credit: …

Cracking open a can of cannabis—America's new pastime (for now)

[ At Fourth of July barbecues this weekend, Americans are more likely than ever to …

Mechanical restraint linked to small increased short-term blood clot risk in psychiatric hospitals

[ Credit: Pixabay/CC0 Public Domain Mechanical restraint is associated with a small increased short-term risk …

Leave a Reply

Available for Amazon Prime